Idera Pharmaceuticals is a clinical-stage patient-focused biopharmaceutical company developing novel nucleic acid therapeutic approaches for the treatment of certain cancers and rare diseases. Idera’s immunotherapy approach is based on the modulation of toll-like receptors (TLRs) while our third-generation antisense technology is designed to inhibit the production of disease-associated proteins by targeting RNA. We are devel...
Idera Pharmaceuticals is a clinical-stage patient-focused biopharmaceutical company developing novel nucleic acid therapeutic approaches for the treatment of certain cancers and rare diseases. Idera’s immunotherapy approach is based on the modulation of toll-like receptors (TLRs) while our third-generation antisense technology is designed to inhibit the production of disease-associated proteins by targeting RNA. We are developing our toll-like receptor agonist, tilsotolimod (IMO-2125) to treat certain solid tumors such as melanoma. We aim to dramatically improve the outcomes for patients suffering from these cancers.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.